↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Collegium Pharmaceutical$COLL · filed: grew revenue 23.6% in FY2025 to $781MNew shipTrillion Score 506Fall Risk MediumNext year $733M–$1.2B sealedCheck ▾Close ▴
What Collegium Pharmaceutical filed
Grew revenue 23.6% in FY2025 to $781 million, operating margin 23.0% against a -3.8% median for pharmaceutical preparations, equity 18.2% of assets. Every figure links to the filing it came from on Collegium Pharmaceutical’s card. New ship: no warning signs. Trillion Score 506, #88 of 182 in its field; Fall Risk Medium (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $733M and $1.2B, an 80% range sealed on 27 Sept 2026 · receipt #e74cc0 · graded in public by the revenue in Collegium Pharmaceutical’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Collegium's **$50M** ASR through Jefferies retires **6%** of float instantly—confidence in ADHD pricing or capital deployment dead-end.
$50 million
accelerated share repurchase through Jefferies
80%
of the shares immediately
18 months
The board authorized a
$100 million
buyback program in late
Collegium Pharmaceutical announced Thursday a $50 million accelerated share repurchase through Jefferies, delivered in pre-market and met with immediate buying. The ADHD-focused drugmaker receives roughly 80% of the shares immediately, with final settlement tied to volume-weighted average price over the execution window. No maturity disclosed, but ASRs of this size typically close in 60 to 90 days.
The structure is clean and orthodox. Collegium pays the full $50 million upfront. Jefferies borrows shares, delivers them to the company for immediate retirement, then works the hedge in the open market without disrupting the tape. The company locks in buyback size today and eliminates execution risk. The trade-off: Collegium surrenders any upside from patient open-market timing and pays the embedded financing cost in the price adjustment.
Collegium's flagship product is Jornay PM, an evening-dosed methylphenidate for ADHD that competes in a category seeing sustained script growth but tightening reimbursement. The ASR arrives as the company navigates patent cliffs and generic encroachment across its older assets. Pricing in ADHD has held—commercial plans have not yet moved to aggressive step edits—but utilization management is tightening in Medicare Advantage and state Medicaid. Collegium's decision to retire $50 million in equity now, rather than preserve dry powder or accelerate pipeline investment, suggests management sees limited near-term deployment opportunities with better risk-adjusted returns than buybacks at current valuation.
This is Collegium's second meaningful capital return in 18 months. The board authorized a $100 million buyback program in late 2023, and this ASR likely exhausts half that authorization in a single trade. The velocity matters. When specialty pharma moves to ASR instead of dribbling buybacks over quarters, it signals one of two postures: materially undervalued equity or a thin pipeline that cannot absorb incremental R&D capital efficiently. Collegium's enterprise value sits near $800 million, so this represents over 6% of market cap retired in one print.
Allocators should track Jornay PM formulary status on 2025 Medicare Advantage plans, published in October. If the product holds preferred status without prior authorization, the ASR reads as offense. If it drops a tier or gains step therapy, this buyback becomes defense—returning cash before the margin compression arrives. Jefferies will be working the hedge through mid-Q2, so any unusual volume or price action in that window reflects mechanical flow, not fresh fundamental news.
Collegium reports Q1 earnings in early May. The ASR will reduce the share count, lifting EPS optically, but the $50 million outflow also depletes balance sheet flexibility for in-licensing or late-stage asset acquisition—the typical growth path for single-product specialty pharma. The Jefferies execution starts now.
Branded by POPS4 · proof in 60 seconds
For the principal
ASR depletes M&A optionality; if Jornay pricing holds through 2025 MA renewals, buyback validates moat—otherwise, it's pre-erosion distribution.
For the operator
Watch Jefferies flow through Q2 for technical distortion; formulary status in October Medicare Advantage publications will confirm offense or reveal defense.
For the house
No position in COLL; monitor Jornay PM tier placement in CMS data—if step edits appear, specialty pharma buybacks become yield plays, not growth.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
